2023
Copenhagen, Denmark, 8 September 2023 – FluoGuide A/S (“FluoGuide” or the “Company”), a pioneer in the...
7 September, 2023
Positive interim data from phase lla trial of FG001 in head & neck cancer presented as a case report at the World Molecular Imaging Congress in Prague
Copenhagen, Denmark, 7 September 2023 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to see...
Copenhagen, Denmark, 30 August 2023 – FluoGuide A/S (“FluoGuide” or the “Company”) today releases its...
29 August, 2023
FluoGuide reports further positive interim data from phase IIa trial of FG001 in head & neck cancer
Copenhagen, Denmark – FluoGuide A/S (“FluoGuide” or the “Company”), a pioneer in the cutting-edge field...
28 August, 2023
FluoGuide completes patient enrollment and treatment in FG001 phase llb clinical trial in aggressive brain cancer
Copenhagen, Denmark – FluoGuide A/S (“FluoGuide” or the “Company”), a pioneer in the cutting-edge field...
28 August, 2023
FluoGuide A/S issues warrants to the investors participating in the directed share issue
Copenhagen, Denmark, 28 August 2023 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce...
Copenhagen, Denmark, 31 July 2023 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce...
Copenhagen, Denmark, 25 July 2023 – FluoGuide A/S (“FluoGuide” or the “Company”) held an extraordinary...
7 July, 2023
FluoGuide convenes an extraordinary general meeting
Copenhagen, Denmark, 7 July 2023 – FluoGuide A/S (“FluoGuide” or the “Company”) hereby invites shareholders...
Calendar &
upcoming reports
30 August 2023
14 September 2023
29 November 2023
28 February 2024